HSP47 might actively promote angiogenesis in glioma through the HIF1α–VEGFR2 pathway.75In bladder cancer, the ERK signaling pathway, in conjunction with C–C motif chemokine ligand 2 (CCL2), fosters HSP47-mediated angiogenesis.76Studies indicate that HSP47 inhibitors can counteract VEGF-driven fibrovascular changes in retinal diseases, reducing the fibrovascular formation that contributes to conditions like retinal fibrosis.77This effect suggests a broader therapeutic potential for HSP47 inhibitors in controlling pathological angiogenesis beyond oncology. Here, SERPINH1 is linked to urinary bladder cancer.